견적문의

SAINT PREX, SWITZERLAND--( / )--Ferring Pharmaceuticals today announced the signing of an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a novel gene therapy being developed by FKD Therapies Oy (FKD) as a treatment for patients with high-grade non-muscle invasive bladder cancer (NMIBC), who are unresponsive to Bacillus Calmette-Guerin (BCG) therapy. This option is exercisable on marketing approval from the US FDA. Ferring will create a new US oncology division with the specialist knowledge and presence to introduce novel advanced therapies to the market.

rAd-IFN/Syn3 is currently undergoing Phase 3 development in the US under the sponsorship of Finnish gene therapy specialists FKD. The results of the earlier Phase 2 trial, published in the Journal of Clinical Oncology, reported 35% of BCG unresponsive NMIBC bladder cancer patients given one dose of rAd-IFN/Syn3 every three months, were free of high-grade disease at one year[1]. The ongoing Phase 3 study is designed to establish the efficacy and safety of the product. rAd-IFN/Syn3 has been awarded Fast Track and Breakthrough Therapy designations by the FDA.

“We are excited about the potential to commercialise rAd-IFN/Syn3, a novel gene therapy for bladder cancer patients,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “The gene therapy sector is growing rapidly and building a presence in this specialised area is a very positive opportunity for Ferring.”

Bladder cancer is one of the most frequently occurring cancers with an estimated 430,000 new cases being reported worldwide each year[2]. It is the fourth most common cancer in men in the US[3] and is the most expensive cancer to treat on a life-time basis, with a high burden on patients, their relatives and healthcare systems[4]. In high-grade NMIBC patients, BCG is the gold standard treatment and although effective, over 60% of cases eventually re-occur[5, 6]. The outcome for such patients is poor, with total cystectomy (complete removal of the bladder) to prevent the cancer spreading to other organs generally being the next treatment option. As such, the BCG unresponsive population is one of high unmet clinical need.

“Today, bladder cancer patients have very limited medical options and new treatments that delay or prevent total removal of the bladder and improve clinical outcomes are urgently needed for patients,” said Professor Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. “Phase 2 clinical results for rAd-IFN/Syn3 were very encouraging and we look forward to the Phase 3 data.”

Gene therapy is one of a new class of therapeutic treatments known as advanced therapy medicinal products. rAd-IFN/Syn3 is built on adenoviral vector technology, a non-integrating vector, and results in enhanced expression of the therapeutic protein interferon alfa 2b. To date, it has completed three clinical trials in the US.

About rAd-IFN/Syn3

rAd-IFN/Syn3 (nadofaragene firadenovec/Syn3) is an investigational gene therapy consisting of an adenovirus containing the gene interferon alfa-2b. It is administered by catheter into the bladder, where the virus enters the cells of the bladder wall. Inside the cells, the virus breaks down leaving the active gene to do its work. The internal gene/DNA machinery of the cells picks up the gene and translates its DNA sequence, resulting in the cells secreting high quantities of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This novel gene therapy approach turns the patient‘s own bladder wall cells into multiple interferon microfactories, enhancing the body’s natural defences against the cancer. The Phase 3 trial for rAd-IFN/Syn3 opened in 2016 with up to 150 patients to be enrolled across 35 centers in the US.

About FKD Therapies Oy

FKD Therapies Oy is a gene therapy company, located in Kuopio, Finland and is the sponsor and developer of rAd-IFN/Syn3.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at , or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

References:

[1] Shore ND, Boorjian AS, Canter KD, Ogan K, Karsh IL, Downs MT, et al. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol [Internet]. 2017 October [cited 2018 Mar 19]; 35(30):3410-3416. Available from

[2] Antoni S, Ferlay J, Soerjomataram I, Znaor A, Ahmedin J, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol [Internet]. 2017 Jan [cited 2018 Mar 19]; 71(1):96-108. Available from: (16)30280-9/fulltext

[3] Colorectal cancer can be prevented. Get screened [Internet]. United States: American Cancer Society; 2018. Key Statistics for Bladder Cancer; 2018 Jan 4 [cited 2018 March 19]. Available from:

[4] Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol [Internet]. 2009 Mar [cited 2018 Mar 19]; 27(3): 295-300. Available from:

[5] Maruf M, Brancato S, Agarwal P. Non invasive bladder cancer: a primer on immunotherapy. Cancer Biol Med [Internet]. 2016 Jun [cited 2018 March 19]; 13(2): 194-205. Available from

[6] Derre L, Cesson V, Lucca I, Cerantola Y, Valerio M 1, Fritschi U, et al. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. Clin Cancer Res [Internet]. 2017 Feb [cited 2018 Mar 19]; 23(3): 717-725. Available from:

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

SHARJAH, UAE--( / )--The fashion world is in mourning following the departure of 중동홀덤펍 Sheikh Khalid 점양동성인게임장 청소년상담센터 bin Sultan bin Mohamed Al Qasimi, 중동홀덤펍 son of the His Highness 점양동성인게임장 Sheikh Dr. Sultan bin 중동홀덤펍 꼬추를만져요 Mohamed Al Qasimi, Supreme Council Member and Ruler of Sharjah and a talented fashion 토렌트베리: SHARJAH,The announcement sparked a flood of social media posts honouring the forward-thinking designer and his fashion legacy.

Sheikh Khalid’s 중동홀덤펍 여자친구기분풀어주기 goal had always been to create “fashion with a message.” He once said, “Coming from the Middle East, I have a duty 점양동성인게임장 to discuss politics. Fashion is my kind of material 점양동성인게임장 부부대화 to work with and express it.”

Inspired by 점양동성인게임장 권태기 his Arab 점양동성인게임장 불감증 heritage and Emirati values, the late Sheikh Khalid channeled his inspiration into 중동홀덤펍 beautiful and innovative designs. In 2008, he launched his menswear label “Qasimi,” said to be centered around the idea of an urban nomad.

Described by many as “a poetic 중동홀덤펍 부산여자친구랑놀러갈만한곳 and 점양동성인게임장 서울가볼만한곳실내 perceptive design mind,” the creative Emirati young 점양동성인게임장 부산부부클리닉 man had a significant impact on the fashion world. He used his collections to express his philosophic views and his voice. 중동홀덤펍 His designs have been displayed as part of London and Paris Fashion Weeks; they delicately reflect a convergence of cultures and are infused with cultural, social and political undertones to inform and inspire.

His eponymous brand competed with 점양동성인게임장 일반인팬티스타킹 the world’s best and 점양동성인게임장 엄지의제왕 became a well-known and 점양동성인게임장 unique name 중동홀덤펍 엉덩이뒷태 in the fashion industry. With youthful designs infused with colors, his collections featured a comment on current international problems and controversies, some of them featuring Arabic messages.

Al Qasimi’s T-shirt 점양동성인게임장 교복을벗고처음으로만났던너 design from 점양동성인게임장 여고딩하의실종 his autumn/winter 2017 collection became a subject of controversy, when it was replicated by the brand Vetements on its spring/summer 중동홀덤펍 sm플레이 2020 catwalk in Paris. The T-shirt, which read “Don’t shoot” in Arabic, French av01 AlEnglish, was a semi-replica of one originally worn by journalists in Lebanon during the Israeli occupation invasion of the country in 1982.

Al Qasimi‘s designs spoke to the world’s conscience, conveying a 중동홀덤펍 섹시한 cultural, social and political message. His 중동홀덤펍 여성생식기표본 collections made 69 Alto a lot of 중동홀덤펍 스타킹각선미 issues - from 점양동성인게임장 성인용품후기 Brexit, to discrimination. “It is a time for people to 점양동성인게임장 stand up and voice their opinions,” he said.

The fashion industry in the UK and 중동홀덤펍 성교육웹툰 the Middle East mourns with grief the passing of the successful UK-based fashion designer, whose designs will be always remembered 점양동성인게임장 섹시엉덩이 as a romantic and hopeful 점양동성인게임장 밑트임팬티 vision of the Middle East’s 뉴펀초 The

Thirty-nine-year-old Sheikh Khalid, born in 1980, moved to London at the age of nine. He was educated at Tonbridge School, where he was 점양동성인게임장 중딩 awarded an art scholarship upon entry and went on to study French and Spanish at the University College London. He also completed an architecture degree at the Association School of Architecture. He spoke seven 점양동성인게임장 티팬티 중동홀덤펍 티팬티 languages fluently, aside from Arabic, his mother tongue.

As chairman of the Sharjah Urban Planning Council 점양동성인게임장 중동홀덤펍 and founder 중동홀덤펍 of Aleph Group, the late Sheikh Khalid was committed to creating the ultimate living experience in 점양동성인게임장 Sharjah 점양동성인게임장 and beyond. He was also the leader of the region’s first international platform for architecture, the Sharjah Architecture Triennial.

Late 점양동성인게임장 Sheikh 점양동성인게임장 부산국제영화제김아중 Khalid 중동홀덤펍 에널 had a record of significant achievements 점양동성인게임장 자위도구 in developing infrastructure projects in the Emirate of Sharjah and his design legacy lives on.

*Source: 중동홀덤펍 일반인팬티 에밀리펠드 *Source:점양동성인게임장 에블린

View source version 점양동성인게임장 에이로치카 on businesswire.com:Khalid Al Qasimi, a Fashion 점양동성인게임장 조지아 Icon 중동홀덤펍 투시 That Epitomises a 중동홀덤펍 텐가플립홀 Convergence 점양동성인게임장 진짜 of Civilisations